Effects of chronic long-term therapy with calcium antagonists on cytogenetic damage in humans

Maria G. Andreassi, Eugenio Picano, Silvia Del Ry, Lucia Petrozzi, Daniela Giannessi, A. Varga

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective. To assess whether chronic long-term calcium antagonist therapy may increase genotoxicity, the chromosome aberration test, a widely accepted genotoxic assay, was used ex vivo in peripheral human lymphocytes of patients with or without long-term exposure to calcium antagonist therapy. Methods and results. In a case-control study design, we evaluated 30 ischaemic and/or hypertensive patients (22 males, eight females; age 59.4 ± 1.5 years), under chronic calcium antagonist treatment (group I), for more than 3 years (4.4 ± 0.34 years) and 30 age-matched subjects, without any previous exposure to calcium antagonists (group II). Venous blood samples were collected from the patients and cultures were set up for cytogenetic analysis by standard methods. For each subject, 100 metaphases were scored. The two groups showed similar values (mean ± SEM) for percentage aberrant cells (group I 2.6 ± 0.3 versus group II 2.5 ± 0.3, not significant), percentage structural aberrations (group I 1.9 ± 0.3 versus group II 1.8 ± 0.2, not significant) and percentage numerical aberrations (group I 0.70 ± 0.2 versus group II 0.73 ± 0.2, not significant). Conclusions. Long-term calcium antagonist therapy is not associated with an increased incidence of chromosomal indices of genotoxic damage in humans.

Original languageEnglish
Pages (from-to)843-846
Number of pages4
JournalJournal of Hypertension
Volume17
Issue number6
DOIs
Publication statusPublished - 1999

Fingerprint

Cytogenetics
Calcium
Therapeutics
Cytogenetic Analysis
Metaphase
Chromosome Aberrations
Case-Control Studies
Lymphocytes
Incidence

Keywords

  • Calcium antagonists
  • Cancer risk
  • Chromosome aberrations
  • Genotoxicity

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology

Cite this

Effects of chronic long-term therapy with calcium antagonists on cytogenetic damage in humans. / Andreassi, Maria G.; Picano, Eugenio; Del Ry, Silvia; Petrozzi, Lucia; Giannessi, Daniela; Varga, A.

In: Journal of Hypertension, Vol. 17, No. 6, 1999, p. 843-846.

Research output: Contribution to journalArticle

Andreassi, Maria G. ; Picano, Eugenio ; Del Ry, Silvia ; Petrozzi, Lucia ; Giannessi, Daniela ; Varga, A. / Effects of chronic long-term therapy with calcium antagonists on cytogenetic damage in humans. In: Journal of Hypertension. 1999 ; Vol. 17, No. 6. pp. 843-846.
@article{b92fd9dddbdf42a1878533c779ae0191,
title = "Effects of chronic long-term therapy with calcium antagonists on cytogenetic damage in humans",
abstract = "Objective. To assess whether chronic long-term calcium antagonist therapy may increase genotoxicity, the chromosome aberration test, a widely accepted genotoxic assay, was used ex vivo in peripheral human lymphocytes of patients with or without long-term exposure to calcium antagonist therapy. Methods and results. In a case-control study design, we evaluated 30 ischaemic and/or hypertensive patients (22 males, eight females; age 59.4 ± 1.5 years), under chronic calcium antagonist treatment (group I), for more than 3 years (4.4 ± 0.34 years) and 30 age-matched subjects, without any previous exposure to calcium antagonists (group II). Venous blood samples were collected from the patients and cultures were set up for cytogenetic analysis by standard methods. For each subject, 100 metaphases were scored. The two groups showed similar values (mean ± SEM) for percentage aberrant cells (group I 2.6 ± 0.3 versus group II 2.5 ± 0.3, not significant), percentage structural aberrations (group I 1.9 ± 0.3 versus group II 1.8 ± 0.2, not significant) and percentage numerical aberrations (group I 0.70 ± 0.2 versus group II 0.73 ± 0.2, not significant). Conclusions. Long-term calcium antagonist therapy is not associated with an increased incidence of chromosomal indices of genotoxic damage in humans.",
keywords = "Calcium antagonists, Cancer risk, Chromosome aberrations, Genotoxicity",
author = "Andreassi, {Maria G.} and Eugenio Picano and {Del Ry}, Silvia and Lucia Petrozzi and Daniela Giannessi and A. Varga",
year = "1999",
doi = "10.1097/00004872-199917060-00017",
language = "English",
volume = "17",
pages = "843--846",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Effects of chronic long-term therapy with calcium antagonists on cytogenetic damage in humans

AU - Andreassi, Maria G.

AU - Picano, Eugenio

AU - Del Ry, Silvia

AU - Petrozzi, Lucia

AU - Giannessi, Daniela

AU - Varga, A.

PY - 1999

Y1 - 1999

N2 - Objective. To assess whether chronic long-term calcium antagonist therapy may increase genotoxicity, the chromosome aberration test, a widely accepted genotoxic assay, was used ex vivo in peripheral human lymphocytes of patients with or without long-term exposure to calcium antagonist therapy. Methods and results. In a case-control study design, we evaluated 30 ischaemic and/or hypertensive patients (22 males, eight females; age 59.4 ± 1.5 years), under chronic calcium antagonist treatment (group I), for more than 3 years (4.4 ± 0.34 years) and 30 age-matched subjects, without any previous exposure to calcium antagonists (group II). Venous blood samples were collected from the patients and cultures were set up for cytogenetic analysis by standard methods. For each subject, 100 metaphases were scored. The two groups showed similar values (mean ± SEM) for percentage aberrant cells (group I 2.6 ± 0.3 versus group II 2.5 ± 0.3, not significant), percentage structural aberrations (group I 1.9 ± 0.3 versus group II 1.8 ± 0.2, not significant) and percentage numerical aberrations (group I 0.70 ± 0.2 versus group II 0.73 ± 0.2, not significant). Conclusions. Long-term calcium antagonist therapy is not associated with an increased incidence of chromosomal indices of genotoxic damage in humans.

AB - Objective. To assess whether chronic long-term calcium antagonist therapy may increase genotoxicity, the chromosome aberration test, a widely accepted genotoxic assay, was used ex vivo in peripheral human lymphocytes of patients with or without long-term exposure to calcium antagonist therapy. Methods and results. In a case-control study design, we evaluated 30 ischaemic and/or hypertensive patients (22 males, eight females; age 59.4 ± 1.5 years), under chronic calcium antagonist treatment (group I), for more than 3 years (4.4 ± 0.34 years) and 30 age-matched subjects, without any previous exposure to calcium antagonists (group II). Venous blood samples were collected from the patients and cultures were set up for cytogenetic analysis by standard methods. For each subject, 100 metaphases were scored. The two groups showed similar values (mean ± SEM) for percentage aberrant cells (group I 2.6 ± 0.3 versus group II 2.5 ± 0.3, not significant), percentage structural aberrations (group I 1.9 ± 0.3 versus group II 1.8 ± 0.2, not significant) and percentage numerical aberrations (group I 0.70 ± 0.2 versus group II 0.73 ± 0.2, not significant). Conclusions. Long-term calcium antagonist therapy is not associated with an increased incidence of chromosomal indices of genotoxic damage in humans.

KW - Calcium antagonists

KW - Cancer risk

KW - Chromosome aberrations

KW - Genotoxicity

UR - http://www.scopus.com/inward/record.url?scp=0033033534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033033534&partnerID=8YFLogxK

U2 - 10.1097/00004872-199917060-00017

DO - 10.1097/00004872-199917060-00017

M3 - Article

VL - 17

SP - 843

EP - 846

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 6

ER -